Local delivery of minocycline and systemic BCNU have synergistic activity in the treatment of intracranial glioma

Journal of Neuro-Oncology

Volumn 64, Issue 3, 2003, Pages 203-209

  Frazier, James L ^a   Wang, Paul P ^a   Case, Daniel ^a   Tyler, Betty M ^a   Pradilla, Gustavo ^a   Weingart, Jon D ^a   Brem, Henry ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

1,3 bis(2 chloroethyl) 1 nitrosourea; 9L gliosarcoma; Angiogenesis; Blood brain barrier; Intracranial delivery; Median survival; Minocycline; Poly bis(p carboxyphenoxy)propane sebacic acid

Indexed keywords

ANTINEOPLASTIC AGENT; CARMUSTINE; MINOCYCLINE; POLY[BIS(4 CARBOXYPHENOXY)PROPANE SEBACIC ACID]; POLYANHYDRIDE; POLYMER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIODEGRADABILITY; BRAIN TUMOR; CANCER GROWTH; CANCER INHIBITION; CANCER SURVIVAL; CANCER TRANSPLANTATION; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DEATH; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; DRUG RELEASE; FEMALE; GLIOMA; GLIOSARCOMA; IN VIVO STUDY; KINETICS; NONHUMAN; RAT; RAT STRAIN;

ABSORBABLE IMPLANTS; ANIMALS; ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CARMUSTINE; DELAYED-ACTION PREPARATIONS; DRUG EVALUATION, PRECLINICAL; DRUG SYNERGISM; FEMALE; GLIOSARCOMA; MINOCYCLINE; NEOPLASM TRANSPLANTATION; RATS; RATS, INBRED F344; TREATMENT OUTCOME;

EID: 0141682487     PISSN: 0167594X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1025695423097     Document Type: Article

References (34)

1. Cheng SY, Huang HJ, Nagane M, Ji XD, Wang D, Shih CC, Arap W, Huang CM, Cavenee WK: Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor. Proc Natl Acad Sci USA 93: 8502-8507, 1996
2. Wesseling P, Ruiter DJ, Burger PC: Angiogenesis in brain tumors; Pathobiological and clinical aspects. J Neuro-Oncol 32: 253-265, 1997
3. Sorensen DR, Read TA, Porwol T, Olsen BR, Timpl R, Sasaki T, Iversen PO, Benestad HB, Sim BK, Bjerkvig R: Endostatin reduces vascularization, blood flow, and growth in a rat gliosarcoma. Neuro-Oncology 4: 1-8, 2002
4. Short SC, Traish D, Dowe A, Hines F, Gore M, Brada M: Thalidomide as an anti-angiogenic agent in relapsed gliomas. J Neuro-Oncol 51: 41-45, 2001
5. Mentlein R, Eichler O, Forstreuter F, Held-Feindt J: Somatostatin inhibits the production of vascular endothelial growth factor in human glioma cells. Int J Cancer 92: 545-550, 2001
6. Sipos EP, Brem H: Local anti-angiogenic brain tumor therapies. J Neuro-Oncol 50: 181-188, 2000
7. Puduvalli VK, Sawaya R: Antiangiogenesis - Therapeutic strategies and clinical implications for brain tumors. J Neuro-Oncol 50: 189-200, 2000
8. Kirsch M, Schackert G, Black PM: Anti-angiogenic treatment strategies for malignant brain tumors. J Neuro-Oncol 50: 149-163, 2000
9. Folkman J: Tumor angiogenesis: Therapeutic implications. N Engl J Med 285: 1182-1186, 1971
10. Folkman J, Merler E, Abernathy C, Williams G: Isolation of a tumor factor responsible for angiogenesis. J Exp Med 133: 275-288, 1971
11. Folkman J: Tumor angiogenesis. In: Holland, Frei E, Bast R et al. (eds) Cancer Medicine, 3rd edn. Lea & Febiger, Philadelphia, 1993, pp 153-170
12. Folkman J: What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82: 4-6, 1990
13. Folkman J: Angiogenic factors. Science 235: 442-447, 1987
14. Folkman J: Antiangiogenesis. In: DeVita VT, Hellman S, Rosenberg SA (eds) Biologic Therapy of Cancer. JP Lippincott, Philadelphia, 1991, pp 743-753
15. Brem S, Cotran R, Folkmann J: Tumor angiogenesis: A quantitative method for histologic grading. J Natl Cancer Inst 48: 347-356, 1972
16. Tamargo RJ, Bok RA, Brem H: Angiogenesis inhibition by minocycline. Cancer Res 51: 672-675, 1991
17. Sotomayor EA, Teicher BA, Schwartz GN, Holden SA, Menon K, Herman TS, Frei E: Minocycline in combination with chemotherapy or radiological therapy in vitro and in vivo. Cancer Chemother Pharmacol 30: 377-384, 1992
18. Teicher BA, Sotomayor EA, Huang ZD: Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease. Cancer Res 52: 6702-6704, 1992
19. Parangi S, O'Reilly M, Christofori G, Holmgren L, Grosfeld J, Folkman J, Hanahan D: Antiangiogenic therapy of transgenic mice impairs de novo tumor growth. Proc Natl Acad Sci USA 93: 2002-2007, 1996
20. Sasamura H, Takahashi A, Miyao N, Yanase M, Masumori N, Kitamura H, Itoh N, Tsukamoto T: Inhibitory effect on expression of angiogenic factors by antiangiogenic agents in renal cell carcinoma. Br J Cancer 86: 768-773, 2002
21. Teicher BA, Holden SA, Ara G, Northey D: Response of the FSaII fibrosarcoma to antiangiogenic modulators plus cytotoxic agents. Anticancer Res 13: 2101-2106, 1993
22. Guerin C, Laterra J, Masnyk T, Golub LM, Brem H: Selective endothelial growth inhibition by tetracyclines that inhibit collagenase. Biochem Biophys Res Commun 188: 740-745, 1992
23. Greenwald RA, Moak SA, Ramamurthy NS, Golub LM: Tetracyclines suppress matrix metalloproteinase activity in adjuvant arthritis and in combination with flurbiprofen, ameliorate bone damage. J Rheumatol 19: 927-938, 1992
24. Sadowski T, Steinmeyer J: Effects of tetracyclines on the production of matrix metalloproteinases and plasminogen activators as well as of their natural inhibitors, tissue inhibitor of metalloproteinases-1 and plasminogen activator inhibitor-1. Inflamm Res 50: 175-182, 2001
25. Kroon AM, Dontje BHJ, Holtrop M, Van Den Bogert C: The mitochondrial genetic system as a target for chemotherapy: Tetracyclines as cytostatics. Cancer Lett 25: 33-40, 1984
26. Weingart JD, Sipos EP, Brem H: The role of minocycline in the treatment of intracranial 9L glioma. J Neurosurg 82: 635-640, 1995
27. Grossman SA, Reinhard C, Colvin OM, Chasin M, Brundrett R, Tamargo RJ, Brem H: The intracerebral distribution of BCNU delivered by surgically implanted biodegradable polymers. J Neurosurg 76: 640-647, 1992
28. Tamargo RJ, Myseros JS, Epstein JI, Yang MB, Chasin M, Brem H: Interstitial chemotherapy of the 9L gliosarcoma: Controlled release polymers for drug delivery in the brain. Cancer Res 53: 329-333, 1993
29. Yang MB, Tamargo RJ, Brem H: Controlled delivery of 1,3-bis (2-chloroethyl)-1-nitrosurea from ethylene-vinyl acetate copolymer. Cancer Res 48: 5103-5107, 1989
30. Langer R, Folkman J: Polymers for the sustained release of proteins and other macromolecules. Nature 263: 797-800, 1976.
31. Brem H, Tamargo RJ, Olivi A, Pinn M, Weingart JD, Wharam M, Epstein JI: Biodegradable polymers for controlled delivery of chemotherapy with and without radiation therapy in the monkey brain. J Neurosurg 80: 283-290, 1994
32. Brem H, Piantadosi S, Burger PC, Walker M, Selker R, Vick NA, Black K, Sisti M, Brem S, Mohr G: Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. Lancet 345: 1008-1012, 1995
33. Valtonen S, Timonen U, Toivanen P, Kalimo H, Kivipelto L, Heiskanen O, Unsgaard G, Kuurne T: Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: A randomized double-blind study. Neurosurgery 41: 44-48, 1997
34. Van Den Bogert C, Van Kernebeek G, De Leij L, Kroon AM: Inhibition of mitochondrial protein synthesis leads to proliferation arrest in the G1-phase of the cell cycle. Cancer Lett 32: 41-51, 1986